Several promising blood-based biomarkers of AD have been evaluated as potential diagnostic tests, including Aβ peptides (Aβ42 and Aβ40), phospho-tau proteins (p-Tau 181, p-Tau 217, and p-Tau 231), and glial fibrillary acidic protein (GFAP). Here, MAPT is linked to Alzheimer disease.